

*AMENDMENTS TO THE CLAIMS*

This listing of claims replaces all prior versions, and listings, of claims in the application.

1.-34. (Cancelled)

35. (Currently Amended) A method of changing the sensory perception of an animal, wherein the method comprises administering to the inner ear a pharmaceutical composition comprising an adenoviral vector selected from the group consisting of adenoviral vector a-subgroup A, B, D, E, or and F subgroups, wherein the adenoviral vector comprises adenoviral vector comprising a nucleic acid sequence encoding *Hath1* *Hath1* operably linked to a promoter that ~~specifically~~ functions in supporting cells of the inner ear, wherein the nucleic acid sequence is expressed to produce *Hath1* *Hath1* resulting in generation of sensory hair cells that allow perception of stimuli in the inner ear.

36.-38. (Cancelled)

39. (Previously Presented) The method of claim 35, wherein the promoter is a *hes-1* promoter.

40. (Previously Presented) The method of claim 35, wherein the adenoviral vector comprises an adenoviral genome having a deficiency in at least one replication-essential gene function of the E1 region.

41. (Previously Presented) The method of claim 40, wherein the adenoviral vector comprises an adenoviral genome having a deficiency in at least one replication-essential gene function of the E4 region.

42. (Previously Presented) The method of claim 41, wherein the adenoviral vector comprises a spacer in the E4 region.

43.-44. (Cancelled)

45. (Previously Presented) The method of claim 35, wherein the pharmaceutical composition further comprises a viral vector comprising a nucleic acid sequence encoding a neurotrophic agent or a proliferating agent.

46. (Currently Amended) The method of claim 45, wherein the ~~viral~~ adenoviral vector comprising the nucleic acid sequence encoding ~~the atonal-associated factor HATH1~~ and the viral vector comprising the nucleic acid sequence encoding the neurotrophic agent or the proliferating agent are the same viral vector.

47. (Previously Presented) The method of claim 45, wherein the neurotrophic agent is a tumor growth factor, brain-derived neurotrophic factor, or nerve growth factor.

48. (Previously Presented) The method of claim 45, wherein the proliferating agent is selected from the group consisting of fibroblast growth factors (FGFs), vascular endothelial growth factors (VEGFs), epidermal growth factor (EGF), E2F, and cell cycle up-regulators.

49. (Cancelled)

50. (Previously Presented) The method of claim 35, wherein the adenoviral vector is of subgroup B or subgroup F.

51. (Previously Presented) The method of claim 50, wherein the adenoviral vector is of serotype 35 or serotype 41.

52. (Previously Presented) The method of claim 35, wherein the adenoviral vector comprises a fiber protein ablated for binding to a coxsackie and adenovirus receptor (CAR).

53. (Previously Presented) The method of claim 35, wherein the adenoviral vector comprises a penton base protein ablated for binding to one or more integrins.